1. Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers
- Author
-
Roger M. Lane, Taher Darreh-Shori, Candice Junge, Dan Li, Qingqing Yang, Amanda L. Edwards, Danielle L. Graham, Katrina Moore, and Catherine J. Mummery
- Subjects
Butyrylcholinesterase ,Cholinergic ,Glial activation ,Innate immune ,Apolipoprotein E ,Amyloid ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Background The authors sought to examine the impact of the K-variant of butyrylcholinesterase (BCHE-K) carrier status on age-at-diagnosis of Alzheimer disease (AD) in APOE4 carriers. Methods Patients aged 50–74 years with cerebrospinal fluid (CSF) biomarker-confirmed AD, were recruited to clinical trial (NCT03186989 since June 14, 2017). Baseline demographics, disease characteristics, and biomarkers were evaluated in 45 patients according to BCHE-K and APOE4 allelic status in this post-hoc study. Results In APOE4 carriers (N = 33), the mean age-at-diagnosis of AD in BCHE-K carriers (n = 11) was 6.4 years earlier than in BCHE-K noncarriers (n = 22, P
- Published
- 2024
- Full Text
- View/download PDF